Burosumab
CAS 1610833-03-8 2 FDA-DMF suppliersBiologic
Overview
Burosumab is a recombinant human monoclonal antibody used for the treatment of X-linked hypophosphatemia (XLH), a rare genetic disorder. It works by binding to and inhibiting fibroblast growth factor 23 (FGF23), thereby increasing phosphate levels and improving bone health.
Therapeutic areas
Bone DiseasesGenetic DisordersPediatric Endocrinology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.